Literature DB >> 20875918

Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study.

Jae-Min Kim1, Seon-Young Kim, Robert Stewart, Joon-An Yoo, Kyung-Yeol Bae, Sung-Won Jung, Min-Soo Lee, Hyeon-Woo Yim, Tae-Youn Jun.   

Abstract

BACKGROUND: Although antidepressants are conventionally given for 4-6 weeks before deciding on response, several reports suggest that early improvement predicts later outcomes. In a naturalistic national cohort study, we sought to investigate the predictive value of early improvement on Hamilton Depression Rating Scale (HAMD) score for later outcomes (depression (HAMD), anxiety (HAMA), global severity (CGI-s) and functioning (SOFAS)), as well as socio-demographic and clinical correlates of early improvement.
METHODS: Participants were recruited from 18 hospitals across South Korea. All met DSM-IV criteria for depressive disorders, scored ≥14 on the HAMD and received antidepressant treatment for up to 12 weeks. Treatment was naturalistic in that each clinician freely decided the types, doses, and regimes of antidepressant and concomitant medications. Early improvement was defined as a reduction in HAMD score of ≥20% compared with baseline within 2 weeks of treatment. Later treatment outcomes were measured at 4, 8, and 12 weeks.
RESULTS: In a recruited sample of 568 patients, early improvement predicted 12 week treatment outcomes with high sensitivity and high negative predictive values. The predictive values for HAMD and HAMA 12-week responses were higher compared to CGI-s and SOFAS responses. Early improvement was associated with higher monthly income, baseline lower anxiety and higher functioning levels. The patients with early improvement more frequently received antidepressant monotherapy. LIMITATIONS: The study was observational, and the treatment modality was naturalistic.
CONCLUSIONS: Early antidepressant improvement strongly predicted later outcomes, and was associated with higher income, lower anxiety, and higher function.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875918     DOI: 10.1016/j.jad.2010.09.007

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

1.  Sub-hubs of baseline functional brain networks are related to early improvement following two-week pharmacological therapy for major depressive disorder.

Authors:  Yuedi Shen; Jiashu Yao; Xueyan Jiang; Lei Zhang; Luoyi Xu; Rui Feng; Liqiang Cai; Jing Liu; Jinhui Wang; Wei Chen
Journal:  Hum Brain Mapp       Date:  2015-04-30       Impact factor: 5.038

2.  The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data.

Authors:  Martin Bares; Tomas Novak; Miloslav Kopecek; Martin Brunovsky; Pavla Stopkova; Cyril Höschl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-22       Impact factor: 5.270

3.  Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

Authors:  Khatereh Sepanjnia; Amirhossein Modabbernia; Mandana Ashrafi; Mohammad-Jafar Modabbernia; Shahin Akhondzadeh
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

Review 4.  Early switching strategies in antidepressant non-responders: current evidence and future research directions.

Authors:  Paul A Kudlow; Roger S McIntyre; Raymond W Lam
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

5.  Relationship of temperament and character in remitted depressed patients with suicidal ideation and suicide attempts--results from the CRESCEND study.

Authors:  Young Sup Woo; Tae-Youn Jun; Yang-Hwan Jeon; Hoo Rim Song; Tae-Suk Kim; Jung-Bum Kim; Min-Soo Lee; Jae-Min Kim; Sun-Jin Jo
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

Review 6.  Therapeutic Strategies for Treatment of Inflammation-related Depression.

Authors:  Miroslav Adzic; Zeljka Brkic; Milos Mitic; Ester Francija; Milica J Jovicic; Jelena Radulovic; Nadja P Maric
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

7.  Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.

Authors:  Wonsuk Choi; Ju-Wan Kim; Hee-Ju Kang; Hee Kyung Kim; Ho-Cheol Kang; Ju-Yeon Lee; Sung-Wan Kim; Robert Stewart; Jae-Min Kim
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

8.  Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders.

Authors:  Wonsuk Choi; Hee-Ju Kang; Ju-Wan Kim; Hee Kyung Kim; Ho-Cheol Kang; Ju-Yeon Lee; Sung-Wan Kim; Robert Stewart; Jae-Min Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.